Fertility Preservation in Young Patients with Endometrial Cancer by Androutsopoulos, Georgios et al.
36 World Journal of Oncology Research, 2016, 3, 36-39  
 
 E-ISSN: 2413-7308/16  © 2016 Cosmos Scholars Publishing House 
Editorial 
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Endometrial cancer (EC) represents the most 
common malignancy of the female genital tract in 
developed countries [1-10]. Based on recent data, the 
average life time risk for EC worldwide is approximately 
1.71%.11 Although the disease mainly affects 
postmenopausal women, approximately 4% of patients 
are younger than 40 years [1-10, 12-15]. In the majority 
of the patients, abnormal uterine bleeding remains the 
most common symptom [1-7, 9, 10, 12, 13].  
According to the recommendations of many 
international scientific societies (ACOG, FIGO, SGO, 
ESGO and ESMO), systematic surgical staging 
represents the initial treatment approach in all patients 
with EC [2-4, 6-10, 12, 16, 17]. This is mainly because 
systematic surgical staging offers many diagnostic, 
prognostic and therapeutic benefits in these patients [2-
4, 6, 8, 12, 16, 17]. The extent of surgery should be 
carefully individualized according to the type of EC and 
the patient’s general medical status [8].  
In this light, patients younger than 40 years who 
wish to preserve their fertility, should be carefully 
counselled that fertility sparing treatment is a non-
standard approach and the available data on outcomes 
is limited [8, 12, 15, 18, 21]. Moreover, they should be 
able to accept close follow-up during and after the 
fertility sparing treatment [8, 12, 19]. Furthermore, they 
should be informed about the need of systematic 
surgical staging in case of treatment failure or after 
childbearing [8, 12, 15, 18, 19, 21].  
In particular, only patients with FIGO stage IA, 
grade 1 and type I (endometrioid) EC are eligible for 
fertility sparing treatment [8, 12, 14, 15, 22]. These  
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patients should have strong desire for fertility 
preservation, no contraindications for medical 
treatment and informed consent about fertility sparing 
treatment [8, 12, 15]. Additionally, they should be 
referred to specialised centres [8, 12, 18].  
An appropriate endometrial specimen should be 
obtained with dilatation and curettage, hysteroscopy or 
office endometrial biopsy [8, 12, 15, 23-26]. However, 
dilatation and curettage is superior to office endometrial 
biopsy, because it provides a better specimen [8, 12, 
23, 24, 26]. The specimen should be examined by an 
expert pathologist, in order to diagnose accurately the 
grade and the type of EC [8, 12, 15, 26]. Additionally, 
the assessment of hormone receptor status (estrogen, 
progesterone) and the expression of molecular 
prognostic markers (p53, Ki-67, HE-4), might provide 
useful information regarding the biologic behavior of 
tumor [8, 12, 14, 15, 27]. Patients with highly 
aggressive tumors are not eligible for fertility sparing 
treatment [8, 12, 15].  
Furthermore, the presence of myometrial invasion 
and/or extrauterine disease (synchronous ovarian 
tumor, ovarian metastases, suspicious retroperitoneal 
nodes) should be evaluated with magnetic resonance 
imaging (MRI), ultrasound and/or computing 
tomography (CT) [8, 12, 15, 26, 28-30]. Magnetic 
resonance imaging is superior to ultrasound and 
computing tomography, in evaluating the depth of 
myometrial invasion in these patients [8, 12, 15, 26, 28-
30]. Laparoscopy, although it is optional, might provide 
useful data regarding disease stage [12, 15].  
Fertility sparing treatment in young patients with 
FIGO stage IA, grade 1 and type I (endometrioid) EC, 
is based on oral progestins [8, 12, 15, 31-33]. The most 
commonly used progestin regimens are 
medroxyprogesterone acetate and megestrol acetate 
[8, 12, 15, 26, 31-33]. The combined use of 
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levonorgestrel releasing intrauterine device with GnRH-
analogues, shows promising results and represents an 
alternative choice [8, 26, 32, 34]. The average daily 
dosage of medroxyprogesterone acetate is 400-600 
mg, while that of megestrol acetate is 160-320 mg  
[8, 12, 15, 35]. Moreover, the average duration of 
treatment with oral progestins is approximately 6 
months [8, 12, 15, 26]. In the past, many patients were 
treated for more than 6 months [15, 36, 37]. 
Nevertheless, there are no evidence to support the 
prolonged use of oral progestins, in order to achieve 
late response [15, 26, 36, 37].  
During the treatment, all patients should be 
evaluated with endometrial sampling (dilatation and 
curettage or hysteroscopy) every 3 months [8, 12, 15, 
26, 32, 38]. After completion of the 6-month treatment, 
they should be further evaluated with magnetic 
resonance imaging in order to assess the response to 
the fertility sparing treatment [8, 12, 15, 26, 29, 38].  
If there is no response after the 6-month treatment 
with oral progestins, then patients should have 
systematic surgical staging according to the 
recommendations of the international scientific 
societies (ACOG, FIGO, SGO, ESGO and ESMO) [2-4, 
6-10, 12, 15-17, 26]. 
On the other hand, if there is a complete response 
after the 6-month period, then patients should be 
referred to a fertility clinic in order to achieve pregnancy 
as soon as possible [8, 12, 15, 39-42]. Worth to notice 
that pregnancy significantly associated with a lower risk 
for recurrence [8, 12, 15, 32, 39]. If they do not wish 
pregnancy at this time, they should continue the 
treatment with oral progestins and they should have a 
re-evaluation every 6 months [8, 12, 15, 26, 32, 39].  
Based on recent studies, the overall response rate 
in EC patients having fertility sparing treatment is 
approximately 75% [8, 12, 15, 20, 26, 39, 43]. 
However, the overall recurrence rate ranges between 
30% and 40% [8, 12, 15, 20, 39, 43]. This is the main 
reason why, all young EC patients should have 
systematic surgical staging after childbearing  
[8, 12, 15, 26].  
In conclusion, fertility sparing treatment using 
progestins is a promising treatment approach for well 
selected young patients diagnosed with FIGO stage IA, 
grade 1 and type I (endometrioid) EC. Nevertheless, 
this management still represents a non-standard 
approach for them [2-4, 6-10, 12, 16, 17]. In this light, 
all patients should be carefully informed about the 
effectiveness of that innovative treatment approach and 
the need of systematic surgical staging in case of 
treatment failure or after childbearing [8, 12, 15, 20, 39, 
43].  
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